Argenx announced new data on VYVGART for presentation at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session. The data highlight the potential for earlier and sustained treatment in patients with myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP).
The findings include deepening improvement in ocular MG and sustained efficacy across a broader range of MG patients. Real-world data from more than 1,100 U.S. patients support earlier treatment. Long-term data reinforce VYVGART’s consistent safety and efficacy profile in CIDP.
Argenx also presented positive Phase 2 results for empasiprubart, another pipeline candidate.